Humanized Mice Model Market

Humanized Mice Model Market Outlook from 2024 to 2034

The humanized mice model market size is expected to reach US$ 101.6 million in 2024. The market is projected to surge at a CAGR of 6.0%, reaching a valuation of US$ 182.0 million in 2034. The market for mice models is expanding due to the increasing need for individualized treatment and an expanding pipeline of pharmaceutical & biopharmaceutical industries.

Precision medicine is becoming popular among cancer patients as a result of growing applications of genetic profiling for the diagnosis and treatment of several tumor types. The use of mice models is expected to rise with the growing demand for precision medicine in the market.

With the use of advanced technology, mice models with pathological diseases that are more humane, such as genetic illnesses, can be created. The efficiency of drugs and their metabolism in physiologically typical settings, such as human organ function and microbial ecology, can also be ascertained using this model.

There is rising demand for humanized mice model from researchers as they represent and replicate more human physiology. This method helps them to discover more accurate non-clinical studies and medications.

Report Attributes	Details
Estimated Humanized Mice Model Market Size (2024E)	US$ 101.6 million
Projected Market Value (2034F)	US$ 182.0 million
Global Humanized Mice Model Market Growth Rate (2024 to 2034)	6.0% CAGR
Cell-based Segment CAGR (2024 to 2034)	6.1%
Oncology Segment CAGR (2024 to 2034)	6.2%
North America Value Share (2024)	42.6%
East Asia Value Share (2024)	11.7%
Key Companies Profiled	THE JACKSON LABORATORY laconic Biosciences, Inc. Genoway S.A. Yecuris Corporation Charles River Laboratories, Inc. Crown Bioscience Inc. Ingenious Targeting Laboratory Inc. orizon Discovery Group plc HuMurine Technologies Trans Genic Inc., Ltd.

Humanized Mice Model Market Trends

Humanized mice models are frequently employed in preclinical drug research to evaluate the safety and effectiveness of possible treatments. The need for these models is set to rise as pharmaceutical and biotechnology industries look for more realistic representations of human biology to test new medications.

More complex gene editing techniques, such as CRISPR/Cas9, have made it possible to create humanized mice models with greater accuracy and efficiency. This pattern accelerated the creation of models and enhanced the modeling of human diseases.

Models using humanized mice, particularly those engrafted with human malignancies, are becoming popular in oncology research. Academics and pharmaceutical sectors increasingly use these models to investigate the biology of cancer, assess possible therapeutic options, and customize cancer treatments.

To improve the creation and use of humanized mice models, academic institutions, pharmaceutical markets, and biotechnology firms are collaborating and forming partnerships. These partnerships aim to pool knowledge, assets, and technological capabilities to tackle intricate scientific problems.

As tailored medicine gains traction, humanized mice models become increasingly important for researching unique treatment outcomes. This pattern is especially noticeable in the immunology and cancer sectors.

Factors Driving Humanized Mice Model Market Share

Models of humanized mice are useful resources for researching infectious disorders, such as those brought on by bacteria, viruses, and parasites. These models aid in the testing of antiviral medications, the evaluation of vaccine candidates, and the understanding of host-pathogen interactions.

Research and development expenditures are still high in the biotechnology and pharmaceutical sectors. Because of this, there is a constant need for trustworthy and accurate preclinical models, such as humanized mice, to aid in creating novel therapeutic approaches.

Factors Restraining Humanized Mice Model Market Forecast

Even with humanized mice, there are ethical issues with using animals for research, which functions as a brake. Concerns regarding animal welfare raised by the public and by regulations are impacting the use of these models.

Despite considerable advancements, humanized mice models still need to represent the intricacy of human physiology and illness accurately. The results' applicability to humans may vary depending on immunological responses and other physiological processes. Economic difficulties are set to arise from the requirement for expensive equipment, specialized workspaces, and knowledgeable staff for gene editing, especially for smaller research organizations and markets.

What Strategies Can Start-ups Employ to Capitalize on Humanized Mice Model Market Opportunities?

Within the market for humanized mice models, pinpoint particular applications or niches with growing demand or unmet needs. Focusing on a certain field, like infectious illnesses or cancer research, is expected to make a start-up stand out and establish itself as the market's leader.

Utilizing the recent developments in gene editing technology and adding components like immunological or humanized microbiota are expected to draw interest from scientists looking for state-of-the-art models. Through partnerships, start-ups can access resources, knowledge, and a larger clientele. Establishing partnerships with well-known companies in the field can help improve their reputation.

Providing scalable and effective processes for producing models of humanized mice is set to drive the expansion of start-ups in the market. Start-ups can become more competitive by managing expenses and accelerating the creation of models by streamlining the production process and maximizing resource use.

Country-wise Insights

China's market is poised for exceptional growth, projecting a remarkable CAGR of 6.7% through 2034. The surge is primarily attributed to the increasing demand for humanized mice models in key countries. The United States dominates the humanized mice model industry, surging at a CAGR of 5.9% by 2034.

Which Factors Position China as a Thriving Market for Humanized Mice Model?

“Growing Biotechnology and Pharmaceutical Industries to Surge Demand in China”

China's humanized mice model market is projected to expand at a CAGR of 6.7% through 2034. Due to its substantial biomedical research activities, thriving pharmaceutical & biotechnology sector, and emphasis on medication discovery, China holds a prominent position in the market. Humanized mice models are set to be used in oncology research, immunology, infectious illnesses, and customized therapy, among other applications in China.

China's biotechnology and pharmaceutical industries mainly drive the need for humanized mice models. These sectors make substantial use of these models in preclinical drug development, where the key goals are to evaluate the safety and effectiveness of possible treatment choices.

Mice models engrafted with human cancers are in high demand due to the growing frequency of cancer research and the focus on creating targeted therapeutics. These models are essential for researching the biology of cancer, evaluating novel medications, and adjusting therapy strategies in China.

The need for humanized mice models with functioning human immune systems is growing along with interest in immunotherapy. These models are key in advancing the field, studying immune responses, and assessing immunotherapeutic drugs.

Why is the United States Dominating the Humanized Mice Model Market?

“Growing Investment in Research and Development in the United States to Uplift Market”

The United States humanized mouse model market is estimated to record a CAGR of 5.9% through 2034. Academic and scientific institutions are the key users of humanized mice models in the United States. By applying these models to several study fields, these organizations help increase consumer’s knowledge of human diseases and possible treatments.

Regulatory frameworks, such as those issued by the government such as the Food and Drug Administration (FDA) in the United States, impact the application of humanized mice models in preclinical research. Adherence to regulatory requirements is essential for the acceptability and utilization of these models in the pharmaceutical development process.

There are both well-established companies and smaller ones, as well as start-ups in the humanized mice model sector in the United States. Innovations in technology, personalized services, and the creation of new models are frequently at the center of competition in the country.

The availability of funds for research and medication development programs from both governmental and private sources supports the market expansion for humanized mice models. Research funds and partnerships with funding bodies facilitate the spread of model applications in the United States.

Category-wise Insights

Based on the model type, the cell-based segment is estimated to surge at a CAGR of 6.1% by 2034. Simultaneously, the genetic segment is anticipated to grow by 5.9% CAGR by 2034. Based on application, the oncology segment marks its dominance in the humanized mice model market at a CAGR of 6.2% by 2034.

Why Are Cell-based Humanized Mice Models Mainly Preferred?

“Increasing Need to Examine Therapeutic Approaches with Cell-based Models”

Based on model type, the cell-based segment is expected to surge at a CAGR of 6.1% by 2034. Cell-based models are important players in the market for humanized mice models, helping to progress several disciplines, including immunology, infectious diseases, cancer, and personalized medicine. Through the engraftment or introduction of human cells into immunodeficient mice, these models enable researchers to examine diseases, therapeutic approaches, and reactions particular to humans.

Humanized mice models with engrafted human cells are frequently employed in oncology research. These models provide an in vivo setting that closely mimics human physiology, enabling researchers to examine tumor growth, metastasis, and response to anticancer medicines.

Models of humanized mice are also used to investigate the human immune system and evaluate immunotherapies. Researchers engraving human hematopoietic stem cells create mice with functioning human immune systems. These models are useful for studying pathogen-specific immune responses and assessing immunotherapeutic treatments.

Why is Oncology Experiencing a Surge in Humanized Mice Model Demand?

“Rising Incidence of Caner to Expand Oncology Application through 2034”

Based on application, the oncology segment is anticipated to rise at a CAGR of 6.2% through 2034. The humanized mouse and rat model market in oncology has been a vibrant area within the larger preclinical research and medication development field. Models of humanized mice are important tools for researching the biology of cancer, metastasis of tumors, and the assessment of possible treatment approaches.

The increasing incidence of cancer and the growing use of mice models in oncology-related drug & vaccine development studies are the key drivers of the oncology segment's growth. For instance, ExpreS2ion Biotech Holding and the University of Bologna signed a research collaboration agreement in 2021 that encompasses testing the new HER2-cVLP breast cancer vaccination program.

Competitive Landscape

Key players in the humanized mice model market include THE JACKSON LABORATORY, laconic Biosciences, Inc., Genoway S.A., Yecuris Corporation, Charles River Laboratories, Inc., Crown Bioscience Inc., Ingenious Targeting Laboratory Inc., orizon Discovery Group plc, HuMurine Technologies, and Trans Genic Inc., Ltd.

The humanized mice model market has a dynamic competitive landscape. Leading companies are focusing on research & development and new formulations to enhance their market presence.

Key companies are further emphasizing environmentally friendly practices and product certifications and satisfying the increased demand for personalized medication. Leading players are preserving their market position and capitalizing on the growing demand by focusing on the quality and innovation of the product.

For instance,

• In October 2021, the non-profit biomedical research organization, The Jackson Laboratory (JAX) in the United States, acquired Charles River Laboratories Japan's Research Models & Services (RMS) division as a wholly-owned subsidiary.
• In February 2019, H.I.G. Capital LLC, through one of its affiliates, acquired Taconic Biosciences Inc.
• In November 2020, The Jackson Laboratory and Beijing Anitec Biotechnology announced a joint venture partnership to improve access and speed to high-quality research models and services in China.

Humanized Mice Model Market Segmentation by Category

• By Model Type:

  • Genetic
  • Cell-based
    • CD-34
    • PBMC

• By Application:

  • Toxicology
  • Oncology
  • Infectious Disease
  • GvHD
  • Regenerative Medicine
  • Neurobiology
  • Others

• By End-user:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes

• By Region:

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • South Asia and the Pacific
  • East Asia
  • Middle East and Africa